Relapsed/refractory B-cell non-Hodgkin's lymphoma
Clinical trials for Relapsed/refractory B-cell non-Hodgkin's lymphoma explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory B-cell non-Hodgkin's lymphoma trials appear
Sign up with your email to follow new studies for Relapsed/refractory B-cell non-Hodgkin's lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising CAR-T therapy trial for lymphoma withdrawn before it began
Disease control CancelledThis study aimed to test a new CAR-T cell therapy that targets a protein called Igβ on cancer cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The trial planned to enroll patients who had already tried at least two other treatments. However, the study …
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough lymphoma: experimental drug JS203 enters human testing
Disease control OngoingThis early-stage study is testing an experimental drug called JS203 in about 104 people with relapsed or refractory B-cell non-Hodgkin's lymphoma, a type of blood cancer. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinkin…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC